Kobe University · Graduate School of Medicine / Faculty of Medicine

Research keywordsinflammatory bowel disease・pregnancy and preconception care・colorectal tumorigenesis・GPR43 signaling・colonic microbiota・ulcerative colitis・Crohn's disease・per-oral endoscopic myotomy

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Pregnancy and Preconception Care for Patients with Inflammatory Bowel Disease.2025 · 2025年08月, Inflammatory intestinal diseases, 10(1) (1), 290 - 303
• The role of LAT1 in AOM/DSS-induced colorectal tumorigenesis2025 · Elsevier BV, 2025年02月, Biochemical and Biophysical Research Communications, 151446 - 151446
• Differences in Coronavirus disease - 19 vaccination related side effects in patients with ulcerative colitis and Crohn's disease in Japan.2022 · BACKGROUND/PURPOSE OF THIS STUDY: It has been recommended that individuals with inflammatory bowel disease (IBD) be vaccinated against Coronavirus disease - 19 (COVID-19). Recently, we documented the incidence of side effects (SEs) after COVID-19 immunization among individuals with IBD in Japan. However, the study did not show differences between the types of IBD or the patients' clinical backgrounds. In this survey, we aimed at investigating whether the frequency of SEs differed among patients with IBD. METHODS: A cross-sectional survey was conducted among adult patients with IBD at Kobe University between March 2022 and September 2022. RESULTS: Total 195 patients, including 134 with ulcerative colitis (UC) and 61 with Crohn's disease (CD), completed the questionnaire and were included in the analysis. Of these, 92.3%, 91.3% and 44.1% received the initial, second and third dose of the COVID-19 vaccine, respectively. The frequency of local symptoms following the initial, second and third dose of the vaccine was comparable between patients with UC and CD (69.6% vs. 72.7%, 64.2% vs. 69.1% and 63.5% vs. 73.9%, respectively). Muscle pain after the initial and second doses of the COVID-19 vaccine was more common among patients treated with corticosteroids (58.1% vs. 37.6% and 60.0% vs. 31.8%, p
• GPR43 suppresses intestinal tumor growth by modification of the mammalian target of rapamycin complex 1 activity in ApcMin/+ mice2021 · S. Karger AG, 2021年, Medical Principles and Practice, 英語

• 潰瘍性大腸炎の個別化医療を目指す慢性炎症を呈する自然免疫系エフェクター細胞の同定 星 奈美子 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2025年04月01日 - 2028年03月31日2025 · KUID parsed section
• ロイシンセンシングによる腫瘍発生機序の解明と予防法の開発 星 奈美子, 森岡 裕香 日本学術振興会, 科学研究費助成事業, 挑戦的研究(萌芽), 神戸大学, 2023年06月 - 2025年03月, 研究代表者2023 · KUID parsed section
• プロスタグランジン合成酵素に着目したクローン病の新規治療法の開発 大井 充 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2023年04月 - 2026年03月, 研究分担者2023 · KUID parsed section
• 自己抗原の同定に基づいた消化器系難病の病態解明と新しい診療体系の確立 児玉 裕三, 星 奈美子, 増田 充弘, 上田 佳秀 日本学術振興会, 科学研究費助成事業, 基盤研究(B), 神戸大学, 2022年04月01日 - 2025年03月31日2022 · KUID parsed section

• Official profile